AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19487625
Drug: Pramipexole (a
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 1.05 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (a D(3) receptor-preferring agonist)
Trial: 15531659
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil plus antioxidants (2.7 g EPA and DHA/d)
Trial: 11417430
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of 19‐nor‐4‐androstene‐3,17‐dione and 56 mg of 19‐nor‐4‐androstene‐3,17‐diol (156 mg total norsteroid per day)
Trial: 9893540
Drug: fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 2 micrograms.kg-1 + ketamine 0.25 mg.kg-1
Trial: 8031484
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B P-35)
Trial: 7972859
Drug: High-potency neuroleptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency neuroleptics treatment for 3 weeks
Trial: 7972859
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no neuroleptic treatment)
Trial: 25426617
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg on day 1 for one 3-week cycle)
Trial: 25426617
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab and Everolimus
Trial: 17394699
Drug: Finasteride (5alpha-reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5alpha-reductase inhibitor)
Trial: 15952679
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion in combination with canal injection for local anaesthesia with Mepivacaine 2% and Adrenalin 1/100,000
Trial: 12364308
Drug: Changes to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes to the order of presenting treatments, improved presentation of information, and redefinition of the non-radical arm.
Trial: 9667262
Drug: Pegylated-liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated-liposomal doxorubicin (20 mg/m2)
Trial: 9667262
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of doxorubicin (20 mg/m2), bleomycin (10 mg/m2), and vincristine (1 mg) (ABV)
Trial: 8110579
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg or 30 mg i.m., 6 hourly
Trial: 2530869
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amlodipine administered intravenously
Trial: 28392080
Drug: High-dose loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose loop diuretic strategy (HDLD-strategy)
Trial: 21994424
Drug: MK-0941 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 10 mg
Trial: 21994424
Drug: MK-0941 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 20 mg
Trial: 21994424
Drug: MK-0941 30
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 30 mg
Trial: 21994424
Drug: MK-0941 40
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 40 mg
Trial: 21994424
Drug: MK-0941 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 (all doses)
Trial: 12492802
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micro g kg‐1
Trial: 12492802
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micro g kg‐1 plus dexamethasone 8 mg
Trial: 9712230
Drug: Fenfluramine 60
RxNorm normalized name: fenfluramine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine 60 mg orally
Trial: 30006653
Drug: Nasal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal lavage with saline solution at room temperature (20 °C)
Trial: 30006653
Drug: Nasal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal lavage with saline solution at body temperature (37 °C)
Trial: 22023518
Drug: Rituximab-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab-containing therapy before transformation
Trial: 22023518
Drug: Rituximab-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab-containing therapy after transformation
Trial: 18766955
Drug: Spironolactone 2
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 2 mg/kg/day for 12 weeks
Trial: 17979861
Drug: Hand-arm bimanual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand-arm bimanual intensive therapy (HABIT); 6 hours per day for 10 days.
Trial: 17979861
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group; no specific intervention mentioned.
Trial: 8848903
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg (n = 18)
Trial: 26509605
Drug: 24-week peginterferon/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week peginterferon/ribavirin treatment
Trial: 26509605
Drug: 48-week peginterferon/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-week peginterferon/ribavirin treatment
Trial: 21083855
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg per day) for 4 weeks
Trial: 19299805
Drug: NS1209 (322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS1209 (322 mg)
Trial: 11137181
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 mcg/daily)
Trial: 6342836
Drug: Timolol maleate,
RxNorm normalized name: Timolol Maleate, Ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol maleate, 10 mg twice daily
Trial: 27710972
Drug: Stopped gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopped gefitinib treatment upon disease progression (n = 35)
Trial: 18424480
Drug: Interferon-beta therapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta therapy
Trial: 12519430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard chemotherapy without specified filgrastim dose)
Trial: 9058693
Drug: Nebulized ouabain
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized ouabain (1 mg)
Trial: 7939931
Drug: Iron tablet
RxNorm normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron tablet 1 (60 mg elemental iron)
Trial: 7939931
Drug: Iron tablet
RxNorm normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron tablet 2 (60 mg elemental iron)
Trial: 7939931
Drug: Aqueous Fe(II)-sulphate
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous Fe(II)-sulphate solution (120 mg elemental iron)
Trial: 3510524
Drug: Nicardipine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (90 mg/day in 3 divided doses)
Trial: 3510524
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg/day in 3 divided doses)
Trial: 21982342
Drug: L-BLP25 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BLP25 plus best supportive care (BSC)
Trial: 12431827
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin at an area under the curve of 5 mg/ml/min on day 1
Trial: 12431827
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 1 every 21 days
Trial: 28872480
Drug: Norepinephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (10 µg)
Trial: 28872480
Drug: Phenylephrine (137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (137 µg)
Trial: 28872480
Drug: Norepinephrine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (8 µg)
Trial: 23266540
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg) administered at bedtime
Trial: 23266540
Drug: Captopril (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (not specified dosage)
Trial: 19361598
Drug: Aspirin (≤325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (≤325 mg/day)
Trial: 19361598
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus extended-release dipyridamole (ER-DP)
Trial: 19361598
Drug: Anticoagulation (warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation (warfarin and other vitamin K antagonists)
Trial: 17018383
Drug: Deferasirox 10
RxNorm normalized name: Deferasirox 100 mg dispersible oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox 10 mg/kg/day (modified after 12 weeks)
Trial: 17018383
Drug: Deferasirox 10
RxNorm normalized name: Deferasirox 100 mg dispersible oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox 10 mg/kg/day (mean dose 11.3 mg/kg/day)
Trial: 17018383
Drug: Deferasirox (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (once-daily dosing)
Trial: 15466880
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg at baseline, 30 mg at months 1, 2, 3, and 6)
Trial: 10906163
Drug: ABT-627 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-627 (20 mg)
Trial: 10906163
Drug: ABT-627 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-627 (5 mg)
Trial: 3252453
Drug: CW dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CW dye laser treatment
Trial: 3252453
Drug: CW argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CW argon laser treatment
Trial: 29486720
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (200 μg)
Trial: 27914744
Drug: Vaccine-naïve controls
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-naïve controls
Trial: 26183611
Drug: GS-5816 150
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5816 150 mg for 3 days
Trial: 26183611
Drug: GS-5816 5-150
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5816 5-150 mg for 3 days
Trial: 26183611
Drug: GS-5816 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5816 (all doses)
Trial: 15507943
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of meperidine
Trial: 11675899
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg orally once daily for 12 weeks
Trial: 9135352
Drug: Light halothane
RxNorm normalized name: Halothane
DrugBank: Halothane (DB01159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Light halothane anaesthesia (1% end-tidal concentration) with propofol (3 mg kg-1)
Trial: 7957980
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 patch, 0.1 mg for 25 days each month (n = 7)
Trial: 7957980
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 with MPA, 10 mg from days 16 to 25 each month (n = 7)
Trial: 7957980
Drug: Oral equine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral equine estrogens, 1.25 mg (n = 8)
Trial: 3621635
Drug: Verapamil (160-480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (160-480 mg/day)
Trial: 3621635
Drug: Atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50-100 mg/day) plus Hydralazine (50-200 mg/day)
Trial: 18627642
Drug: 2% dorzolamide/0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% dorzolamide/0.5% timolol fixed combination (DTFC)
Trial: 16640481
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (topical anesthetic) with no distraction
Trial: 1639879
Drug: Codeine syrup
RxNorm normalized name: TUSSIREX W/CODEINE SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine syrup B.P. (30 mg/10 ml, q.d.s.)
Trial: 1639879
Drug: Syrup vehicle
RxNorm normalized name: Base PCCA Syrup Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup vehicle (placebo)
Trial: 6711556
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of maintenance therapy (n = 8)
Trial: 6711556
Drug: 15 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 months of maintenance therapy (n = 13)
Trial: 8071266
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (18 sessions of CBT plus desipramine withdrawn at 24 weeks)
Trial: 8071266
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (CBT) alone (18 sessions)
Trial: 2920585
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg every 12 h
Trial: 2920585
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg every 12 h
Trial: 2920585
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg every 12 h
Trial: 1084093
Drug: Simultaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous vaccination with BCG and measles vaccine
Trial: 1084093
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine alone
Trial: 1084093
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine alone
Trial: 28502280
Drug: Custom oral
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Custom oral appliance treatment
Trial: 25279818
Drug: Noribogaine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 3 mg
Trial: 25279818
Drug: Noribogaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 10 mg
Trial: 25279818
Drug: Noribogaine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 30 mg
Trial: 24107875
Drug: Piascledine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piascledine (300 mg daily for two months, combined with artrosilene 320 mg daily for the first month)
Trial: 24107875
Drug: Artrosilene (NSAIDs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artrosilene (NSAIDs, monotherapy)
Trial: 15710002
Drug: FLCA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLCA group (famotidine 20 mg b.d., lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Trial: 15710002
Drug: LCA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCA group (lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Trial: 9706928
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100 microg
Trial: 9706928
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intrathecal neostigmine 12.5 microg and morphine 50 microg
Trial: 9706928
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution 0.2 mL
Trial: 2118925
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN) for 2 weeks
Trial: 28857595
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 3.5 months
Trial: 21878070
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus ethylmethylhydroxypyridine succinate
Trial: 11557167
Drug: Naltrexone 0
RxNorm normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 0 mg (Control)
Trial: 9644751
Drug: Co-amoxiclav 625
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 625 mg 3 times a day for 10 days
Trial: 8043072
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in serum cholesterol concentration of 0.6 mmol/l (about 10%)
Trial: 30337273
Drug: BVS857 (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVS857 (0.06 mg/kg intravenously once a week for 12 weeks)
Trial: 27571927
Drug: Atezolizumab in
RxNorm normalized name: atezolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab in combination with bevacizumab
Trial: 27571927
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Atezolizumab + Bevacizumab)
Trial: 23272986
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy (mindfulness‐based stress reduction and some cognitive behavioral therapy elements for BDS)
Trial: 23272986
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (2‐hour specialist medical care and brief cognitive behavioral therapy for BDS)
Trial: 7577405
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg for children 6-10 years and 50 mg for children 10-14 years)
Trial: 7577405
Drug: Amitriptyline/Desmopressin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline/Desmopressin combination
Trial: 2196771
Drug: Propranolol 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 180 or 240 mg/day
Trial: 23447078
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (250 mg acipimox tablet)
Trial: 23447078
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (250 mg acipimox tablet)
Trial: 19301086
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg, 1 h prior to incision, re-administered once daily on postoperative days 1-4)
Trial: 14984373
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available herbal preparation STW 5
Trial: 14984373
Drug: Research herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research herbal preparation STW 5‐II
Trial: 11317478
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg cerivastatin daily for 7 days
Trial: 10726721
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan/12.5 mg hydrochlorothiazide (L50H12.5C)
Trial: 10726721
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg losartan monotherapy (L100)
Trial: 8873542
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Trial: 8873542
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Trial: 8873542
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Trial: 1567188
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant alpha-2 interferon gel, applied four times daily for four days
Trial: 1567188
Drug: Placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied four times daily for four days
Trial: 29734823
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplement (SQ-LNS) 20 g/d